Jones Cecilia's Form 4 filing
Agios Pharmaceuticals, Inc. (AGIO) · filed Jan 2, 2026
- Accession no.
- 0001439222-26-000002
- Filed
- Jan 2, 2026
- Trade date
- Dec 30, 2025
- Filing delay
- 3 days
- Rule 10b5-1 plan
- Checked
This filing lists 2 non-derivative transactions and 1 derivative transaction. Open-market sales total $79.4K. It was filed 3 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Jones CeciliaCIK 0001840056 | Officer (Chief Financial Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Dec 30, 2025 | Common stock | MOption exerciseAcquired | +6,000 | $0.00 | $0 | 40,326 | Direct | |
| Dec 30, 2025 | Common stock | SSaleDisposed | −2,932 | $27.09 | −$79,427.88 | 37,394 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Dec 30, 2025 | Common stock | MOption exerciseDisposed | −6,000 | $0.00 | $0 | 0 | Direct |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.